Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.61 |
| ▸ | XDH | P47989 | 1/20 | 0.47 |
| ▸ | POLA1 | P09884 | 1/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.40 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | PNP | P00491 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7736838 | 0.98 | DPP4 (0.59) | DPP4XDHPOLA1PDPK1GDA | |
| SCHEMBL27511972 | 0.88 | DPP4 (0.50) | DPP4XDHPOLA1PDPK1GDA | |
| SCHEMBL29366073 | 0.79 | PDPK1 (0.44) | DPP4XDHPDPK1GDAADORA3 | |
| SCHEMBL37384 | 0.79 | DPP4 (0.66) | DPP4XDHPDPK1GDAADORA3 | |
| SCHEMBL20611894 | 0.79 | PDPK1 (0.44) | DPP4XDHPDPK1GDAADORA3 | |
| Hydrochloric Acid SCHEMBL4763244 | 0.78 | DPP4 (0.63) | DPP4XDHPOLA1PDPK1GDA | |
| SCHEMBL11456967 | 0.78 | DPP4 (0.63) | DPP4XDHPOLA1PDPK1GDA | |
| SCHEMBL8719273 | 0.78 | DPP4 (0.63) | DPP4XDHPOLA1PDPK1GDA | |
| Ammonia Solution, Strong SCHEMBL27800067 | 0.78 | XDH (0.44) | DPP4XDHPDPK1GDAADORA3 | |
| SCHEMBL11878673 | 0.77 | DPP4 (0.58) | DPP4XDHPOLA1PDPK1GDA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146059-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-12459967-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ARCUS BIOSCIENCES, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| CN-119912510-A | Modulators of extracellular 5' -nucleotidases and uses thereof | 艾库斯生物科学有限公司 | 2025-05-02 | — | — | CN | disclosed |
| CN-114395005-B | Modulators of extracellular 5' -nucleotidases and uses thereof | 艾库斯生物科学有限公司 | 2024-12-31 | — | — | CN | disclosed |
| US-20240352057-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ARCUS BIOSCIENCES, INC. | 2024-10-24 | — | — | US | disclosed |
| CN-108697719-B | Modulators of extracellular 5' -nucleotidases and uses thereof | 艾库斯生物科学有限公司 | 2024-03-19 | — | — | CN | disclosed |
| EP-4306525-A2 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | Arcus Biosciences, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| EP-3399984-B1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ARCUS BIOSCIENCES INC (US) | 2023-09-06 | — | — | EP | disclosed |
| CN-116492347-A | Compound for activating AMPK and application thereof | 华安医学股份有限公司 | 2023-07-28 | — | — | CN | disclosed |
| US-11667662-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ARCUS BIOSCIENCES, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| EP-1457495-A1 | Adenosine A1 receptor agonists | GLAXO GROUP LIMITED (GB) | 2004-09-15 | — | — | EP | disclosed |
| EP-1030857-B1 | ADENOSINE A1 RECEPTOR AGONISTS | GLAXO GROUP LTD (GB) | 2004-08-18 | — | — | EP | disclosed |
| US-6455510-B1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2002-09-24 | — | — | US | disclosed |
| CN-1285843-A | Compound (I) | GLAXO GROUP LTD (GB) | 2001-02-28 | — | — | CN | disclosed |
| EP-1030857-A2 | ADENOSINE A1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2000-08-30 | — | — | EP | disclosed |
| US-6096724-A | O(6)-ALKYLGUANINE-DNA ALKYLTRANSFERASE (ATASE) ENZYME INHIBITORS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2000-08-01 | — | — | US | disclosed |
| US-5929046-A | Pyrimidine and purine derivatives and their use in treating tumour cells | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1999-07-27 | — | — | US | disclosed |
| WO-1999024449-A2 | ADENOSINE A1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 1999-05-20 | — | — | WO | disclosed |
| EP-0874848-A1 | PYRIMIDINE DERIVATIVES AND GUANINE DERIVATIVES, AND THEIR USE IN TREATING TUMOUR CELLS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1998-11-04 | — | — | EP | disclosed |
| WO-1997020843-A1 | PYRIMIDINE DERIVATIVES AND GUANINE DERIVATIVES, AND THEIR USE IN TREATING TUMOUR CELLS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1997-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240352057-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ENTPD5, NT5C2, NT5E | DPP4 849/4885XDH 280/4885POLA1 605/4885 |
| US-12459967-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ENTPD5, NT5C2, NT5E | DPP4 863/4885XDH 280/4885POLA1 592/4885 |
| US-11667662-B2 | Modulators of 5′-nucleotidase, ecto and the use thereof | ENTPD5, NT5C2, NT5E | DPP4 863/4885XDH 280/4885POLA1 592/4885 |
| US-20260146059-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | NTPCR, NT5C2, NT5E | DPP4 2200/4885XDH 57/4885POLA1 1166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.